Latest Caris Diagnostics Stories
IRVING, Texas and PHOENIX, Aug.
IRVING, Texas, Aug. 1 /PRNewswire/ -- CDX Holdings, a newly-formed holding company that is the parent company of Caris Diagnostics (Caris Dx) and Caris Molecular Diagnostics (CMDx), announced today that George Poste, D.V.M., Ph.D, F.R.C.
IRVING, Texas and PHOENIX, June 24 /PRNewswire/ -- Caris Diagnostics (Caris Dx), a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing, announced that it is now offering KRAS mutation analysis, designed to provide information on which colon cancer patients are most likely to respond to cetuximab (Erbitux) co-marketed by ImClone and Bristol-Myers Squibb or panitumumab (Vectibix)...
IRVING, Texas and PHOENIX, Dec. 6 /PRNewswire/ -- Caris Diagnostics, the leading provider of subspecialty focused pathology services to outpatient physicians, today announced that it has entered into a definitive agreement to combine with Molecular Profiling Institute, Inc.
Caris Diagnostics, the leading provider of subspecialty focused pathology services to outpatient physicians, today announced the expansion of its dermatopathology team through the addition of three highly-respected and accomplished physicians. Mary Landau-Levine, M.D.
- A poem in which the author retracts something said in an earlier poem.